Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594121 | 0.91 | CYP2D6 (0.49) | CYP2D6KCNH2HRH3 | |
| SCHEMBL24827973 | 0.87 | CYP2D6 (0.46) | CYP2D6KCNH2HRH3 | |
| SCHEMBL25518688 | 0.87 | CYP2D6 (0.46) | CYP2D6KCNH2HRH3 | |
| SCHEMBL24827986 | 0.86 | HRH3 (0.38) | CYP2D6KCNH2HRH3 | |
| SCHEMBL24828018 | 0.82 | CYP2D6 (0.36) | CYP2D6KCNH2HRH3 | |
| SCHEMBL4099236 | 0.78 | HRH3 (0.50) | CYP2D6KCNH2HRH3 | |
| SCHEMBL21025310 | 0.78 | HRH3 (0.50) | CYP2D6KCNH2HRH3 | |
| SCHEMBL1104717 | 0.78 | HRH3 (0.50) | CYP2D6KCNH2HRH3 | |
| SCHEMBL23594390 | 0.78 | CYP2D6 (0.40) | CYP2D6KCNH2HRH3 | |
| SCHEMBL24827821 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | BTK, BLK, SYK | CYP2D6 3342/4885KCNH2 346/4885HRH3 2159/4885 |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | CYP2D6 755/4885KCNH2 1931/4885HRH3 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.